NOW APPROVED

ONCE-WEEKLY wegovy™ semaglutide injection 2.4 mg

How to order and dispense Wegovy™

A once-weekly GLP-1 RA for chronic weight management

Wegovy™ comes in 5 packs (one for each strength). Each pack contains 4 Wegovy™ pens (one pen for each week).

					3-month prescription can be written for 2.4 mg dose*	
Strength	 0.25 mg/0.5 mL	 0.5 mg/0.5 mL	 1 mg/0.5 mL	 1.7 mg/0.75 mL	 2.4 mg/0.75 mL	
NDC	0169-4525-14	0169-4505-14	0169-4501-14	0169-4517-14	0169-4524-14	
Days Supply	28 days	28 days	28 days	28 days	28 days	84 days*
Dispense quantity	2 mL (mL only)	2 mL (mL only)	2 mL (mL only)	3 mL (mL only)	3 mL (mL only)	9 mL* (mL only)
Recommended Sig	Inject 0.25 mg SC once weekly for 4 weeks (28 days)	Inject 0.5 mg SC once weekly for 4 weeks (28 days)	Inject 1 mg SC once weekly for 4 weeks (28 days)	Inject 1.7 mg SC once weekly for 4 weeks (28 days)	Inject 2.4 mg SC once weekly for 4 weeks (28 days)	Inject 2.4 mg SC once weekly for 12 weeks (84 days*)
Dispense as written	Check the "dispense as written" (DAW) box					
Notes to pharmacy	Please dispense brand name Wegovy™, not to be confused with other semaglutide-containing products					

*A 3-month supply for appropriate patients would be dispensed as 3 packs, each containing 4 Wegovy™ 2.4 mg dose single-use pens (2.4 mg/0.75 mL) for a total dispense quantity of 9 mL.
EHR, electronic health record; GLP-1 RA, glucagon-like peptide-1 receptor agonist; SC, subcutaneous.

Patients may receive a Wegovy™ patient starter kit at their physician's o ce that contains a 1-month supply of four 0.25 mg Wegovy™ pens. If so, their next prescription may be the 0.5 mg dose.

Storage and handling for Wegovy™

- Store Wegovy™ pen in refrigerator from 36°F to 46°F (2°C to 8°C)
- If needed, prior to cap removal, Wegovy™ pens can be kept from 46°F to 86°F (8°C to 30°C) up to 28 days
- Do not freeze
- Protect Wegovy™ from light
- Wegovy™ must be kept in the original carton until time of administration
- Discard the Wegovy™ pen after use

Indications and Usage

Wegovy™ (semaglutide) injection 2.4 mg is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of ≥30 kg/m^2 (obesity) or ≥27 kg/m^2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).

Limitations of Use

- Wegovy™ contains semaglutide and should not be coadministered with other semaglutide-containing products or with any GLP-1 receptor agonist.
- The safety and e ectiveness of Wegovy™ in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.
- Wegovy™ has not been studied in patients with a history of pancreatitis.

Important Safety Information

WARNING: RISK OF THYROID C-CELL TUMORS

- **In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Wegovy™ causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.**
- **Wegovy™ is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Wegovy™ and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Wegovy™.**

Contraindications

- Wegovy™ is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Wegovy™. Serious hypersensitivity reactions, including anaphylaxis and angioedema have been reported with semaglutide.

Warnings and Precautions

- **Risk of Thyroid C-Cell Tumors:** Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging.
- **Acute Pancreatitis:** Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide. Acute pancreatitis was observed in patients treated with Wegovy™ in clinical trials. Observe patients carefully for signs and symptoms of acute pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back, and which may or may not be accompanied by vomiting). If acute pancreatitis is

novo nordisk®

Please see additional Important Safety Information throughout.
Please click here for Prescribing Information, including Boxed Warning.

ONCE-WEEKLY wegovy™ semaglutide injection 2.4 mg

INFORMATION FOR YOUR PHARMACY

Obtaining the Wegovy™ savings offer is eas

Eligible* patients will pay $25 per 28-day prescription for up to 6 fill

- For patients with a Wegovy™ prescription and **a savings offer** Fulfill the egovy™ prescription and process the savings offer p ovided
- For patients with a Wegovy™ prescription **without a savings offer** Ask them to call **1-833-4-WEGOVY** and press 2

If a patient is covered, a NovoCare® specialist will provide them with savings offer information over the phone or by email. Patients will need to activate the savings offe on **SaveOnWegovy.com** and provide you with the "activated" savings offer to p ocess

*Eligibility and restrictions apply. For eligible commercially insured patients with coverage for branded anti-obesity medications, whose coverage is confirmed via a benefits verification. vo Nordisk reserves the right to modify or cancel this program at any time. See terms and conditions at **wegovyterms2021.com**.

Wegovy™ Pharmacy Connect is here to help

1-888-870-3739 or WPharmacyConnect@connectiverx.com

Representatives available
24 hours a day, 7 days a week

Call the Wegovy™ Pharmacy Connect hotline for help in processing the savings offe .

If an eligible† patient needs to step back their dose

They can pay as little as $0 by calling 1-833-4-WEGOVY

†Eligibility and restrictions apply. For eligible commercially insured patients currently using another Wegovy™ co-pay card offe , if such patients are prescribed a dose de-escalation within 21 days after the date of fill for th original dose. Maximum benefit of an additional $25 off the pat nt's existing co-pay offe . Novo Nordisk reserves the right to modify or cancel this program at any time. See terms and conditions at **wegovyterms2021.com**.

Important Safety Information (cont'd)

Warnings and Precautions (cont'd)

suspected, discontinue Wegovy™ promptly, and if acute pancreatitis is confirmed, do not estart.

- **Acute Gallbladder Disease:** In clinical trials, cholelithiasis was reported by 1.6% of Wegovy™ patients and 0.7% of placebo patients. Cholecystitis was reported by 0.6% of Wegovy™ patients and 0.2% of placebo patients. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated.
- **Hypoglycemia:** Wegovy™ lowers blood glucose and can cause hypoglycemia. In a trial of patients with type 2 diabetes, hypoglycemia was reported in 6.2% of Wegovy™ patients versus 2.5% of placebo patients. Patients with type 2 diabetes taking Wegovy™ with an insulin secretagogue (e.g. sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Inform patients of the risk of hypoglycemia and educate them on the signs and symptoms. Monitor blood glucose in patients with type 2 diabetes.
- **Acute Kidney Injury:** There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which in some cases required hemodialysis, in patients treated with semaglutide. Patients with renal impairment may be at a greater risk of acute kidney injury, but some events have been reported in patients without known underlying renal disease. A majority of the events occurred in patients who experienced nausea, vomiting, or diarrhea, leading to volume depletion. Monitor renal function when initiating or escalating doses of Wegovy™ in patients reporting severe adverse gastrointestinal reactions and in patients with renal impairment reporting any adverse reactions that could lead to volume depletion.
- **Hypersensitivity:** Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with semaglutide. If hypersensitivity reactions occur, discontinue use of Wegovy™, treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist.
- **Diabetic Retinopathy Complications in Patients with Type 2 Diabetes:** In a trial of patients with type 2 diabetes, diabetic retinopathy was reported by 4.0% of Wegovy™ patients and 2.7% of placebo patients. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
- **Heart Rate Increase:** Mean increases in resting heart rate of 1 to 4 beats per minute (bpm) were observed in Wegovy™ patients compared to placebo in clinical trials. More Wegovy™ patients compared with placebo had maximum changes from baseline of 10 to 19 bpm (41% versus 34%) and 20 bpm or more (26% versus 16%). Monitor heart rate at regular intervals and instruct patients to report palpitations or feelings of a racing heartbeat while at rest. If patients experience a sustained increase in resting heart rate, discontinue Wegovy™.
- **Suicidal Behavior and Ideation:** Suicidal behavior and ideation have been reported in clinical trials with other weight management products. Monitor patients for depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Discontinue Wegovy™ in patients who experience suicidal thoughts or behaviors and avoid in patients with a history of suicidal attempts or active suicidal ideation.

Adverse Reactions

- The most common adverse reactions reported in ≥5% of patients treated with Wegovy™ are nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distention, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gast oenteritis, and gastroesophageal reflux disease

Drug Interactions

- The addition of Wegovy™ in patients treated with insulin has not been evaluated. When initiating Wegovy™, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia.
- Wegovy™ causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. Monitor the effects of o al medications concomitantly administered with Wegovy™.

Use in Specific Population

- **Pregnancy:** May cause fetal harm. When pregnancy is recognized, discontinue Wegovy™. Discontinue Wegovy™ in patients at least 2 months before a planned pregnancy.

Reference: Wegovy™ [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; 2021.

Please see additional Important Safety Information throughout. Please click here for Prescribing Information, including Boxed Warning.

novo nordisk®

ONCE-WEEKLY
wegovy™
semaglutide injection 2.4 mg